We are live on
!
Find out more
GC
GMT Capital Portfolio holdings
AUM
$2.19B
1-Year Est. Return
72.3%
This Fund
S&P 500
This Quarter
Est. Return
+1.77%
1 Year Est. Return
+72.3%
3 Year Est. Return
+172.46%
5 Year Est. Return
+183.05%
10 Year Est. Return
+942.8%
AUM
$2.71B
AUM Growth
-$153M
(-5.3%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-4.07%
Top 10 Holdings %
Top 10 Hldgs %
54.19%
Holding
94
New
11
Increased
19
Reduced
28
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Takeda Pharmaceutical
TAK
|
+$20.4M |
| 2 |
Canadian Natural Resources
CNQ
|
+$15.8M |
| 3 |
WUBA
58.com Inc
WUBA
|
+$15M |
| 4 |
SHOE
Shoe Station Group
SHOE
|
+$14.5M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$11.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$27.8M |
| 2 |
LKQ Corp
LKQ
|
+$23.6M |
| 3 |
Arrow Electronics
ARW
|
+$19.2M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$19.1M |
| 5 |
WLH
WILLIAM LYON HOMES
WLH
|
+$18.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 24.96% |
| 2 | Technology | 16.94% |
| 3 | Consumer Discretionary | 13.08% |
| 4 | Communication Services | 12.35% |
| 5 | Energy | 8.02% |
Similar funds
CFM
PCM
ORCP
SQA
CAG
ALMGDA
PVI
ICM
GMT Capital's Q3 2019 Portfolio in Review
As of Q3 2019, GMT Capital held 94 positions worth $2.71B, down 5.3% from $2.86B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
GMT Capital withdrew a net $110M in Q3 2019, closing 6 positions and reducing 28 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $19.1M position sold in full.
By sector, the portfolio is most concentrated in Materials at 25% of assets, down from 27% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, GMT Capital opened a new position in Pioneer Natural Resource Co. worth $11.3M.
- GMT Capital's largest Q3 2019 buy was Pioneer Natural Resource Co.: 89,700 shares worth $11.3M.
- GMT Capital added most to Takeda Pharmaceutical in Q3 2019, an estimated $20.4M increase.
- GMT Capital's biggest Q3 2019 reduction was Celanese, cutting an estimated $27.8M.
- GMT Capital fully exited Sarepta Therapeutics in Q3 2019, selling an estimated $19.1M.
- GMT Capital's ten largest holdings make up 54% of its $2.71B portfolio in Q3 2019.
- GMT Capital opened 11 new positions and closed 6 in Q3 2019.
- GMT Capital's portfolio value fell 5.3% quarter-over-quarter to $2.71B.
Based on GMT Capital's 13F filing for Q3 2019, filed 13 Nov 2019.